Explore cutting-edge studies in tumor biology, molecular pathways, and clinical breakthroughs
Learn how the groundbreaking MURANO trial established venetoclax plus rituximab (VenR) as a transformative fixed-duration therapy for relapsed/refractory chronic lymphocytic leukemia (CLL).